Immutep Ltd
IMM•Health Care•Biotechnology•Last updated: Dec 25
About
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company operates primarily through its lead product candidate, eftilagimod alpha (IMP321), which is a soluble LAG-3 protein used in combination with other therapies to enhance immune responses. Immutep also has a pipeline of other LAG-3 related products in various stages of development.
Share Price Chart
Company Details
- Sector
- Health Care
- Industry
- Biotechnology
- ASX Code
- IMM
Related Shares
Investor Resources
Should you buy Immutep Ltd right now?
While IMM looks interesting right now, our experts have just put together a full report on the ultimate ASX investment portfolio - designed for growth and passive income.
Join the Rask weekly investment newsletter to get the names, right now